All articles tagged with #leucovorin
FDA approves leucovorin for a rare disorder without new trial data, while STAT reports that Boris Nikolic—once linked to Jeffrey Epstein—was quietly helped by investor Alexis Borisy to stage a biotech comeback, and notes ongoing probes into FDA drug-rejection decisions.
The FDA updated the leucovorin label to treat cerebral folate deficiency caused by FOLR1 mutations (CFD-FOLR1), a ultrarare condition linked to autism features, approving the drug based on published case reports and mechanistic rationale rather than a randomized trial. The decision narrows the target population to CFD-FOLR1 after reviewers found the highest-quality data in this subgroup; the move relies on real-world evidence and a plausible mechanism pathway. GSK will stop manufacturing Wellcovorin, but generics exist and importation is allowed; broader autism use remains controversial and calls for more research.
The FDA said leucovorin will be approved only for cerebral folate deficiency (CFD-FOLR1) and will not be expanded to autism, despite the Trump administration’s push. Regulators cited limited evidence for autism treatment and noted a retraction of a key study, narrowing the review to the rare CFD-FOLR1 condition and highlighting the gap between political claims and scientific proof for autism therapies.
The FDA approved leucovorin only for cerebral folate deficiency caused by pathogenic FOLR1 variants, not as a treatment for autism, despite earlier pitches by officials that it could help many autistic children. The supporting evidence for autism benefit has been weak and a major trial was retracted due to data concerns. The rare genetic form this approval covers affects a small number of cases, and the agency is encouraging more research to assess any broader autism effects while signaling the treatment’s utility remains limited to the specific cerebral folate deficiency condition.
FDA officials say there’s insufficient data to approve leucovorin for autism, reversing earlier optimism from RFK Jr. and FDA Commissioner Makary; the drug is now approved for a rare CFD-FOLR1–related cerebral folate deficiency, with off-label autism use left to physician discussion and future research; the initial trial cited in support of autism benefits was retracted, underscoring data limitations.
The FDA approved leucovorin for cerebral folate deficiency and clarified it is not approved to treat autism; data on autism efficacy is insufficient, though doctors may prescribe it off-label, and prescriptions rose after earlier statements from officials.
The FDA approved leucovorin (folinic acid) as the first treatment for cerebral folate deficiency—a rare genetic disorder that prevents folate from reaching the brain—in select adults and children. The decision was based on a systematic review of published case data rather than a randomized trial and did not establish broad efficacy for autism, though future autism studies remain possible. The approval covers generic leucovorin and GSK’s Wellcovorin, and regulators urged manufacturers to boost production to meet rising demand; GSK has no plans to relaunch the product.
The demand for leucovorin, a drug touted by President Trump for autism treatment, is rising despite limited and small-scale scientific evidence. Doctors are cautious, emphasizing the need for more robust research before widespread prescribing, while families and online communities are increasingly interested in its potential benefits.
Parents are rushing to use leucovorin, an old drug promoted by President Trump for autism, despite limited scientific evidence, leading to concerns among medical professionals about unproven treatments and safety.
The article advocates for establishing a national patient registry for leucovorin used in autism treatment, emphasizing that while fast-tracking the drug could benefit patients, it necessitates rigorous post-market surveillance to ensure safety and efficacy, thereby balancing regulatory flexibility with scientific accountability.
A researcher discusses the limited and modest benefits of leucovorin in autism treatment, emphasizing that it is not a cure but may help a subgroup with cerebral folate deficiency, while cautioning parents against unrealistic expectations. The article also critiques recent political claims linking autism to pregnancy factors without solid scientific evidence.
Families have been using leucovorin, a drug originally for cancer, to treat autism symptoms, gaining attention after President Trump mentioned it. While some studies suggest potential benefits, the evidence is limited and the FDA's recent move to update the drug's label is considered unusual and controversial due to weak supporting data. Experts emphasize the need for more research and caution in its use.
The FDA approved leucovorin, a vitamin B derivative, as a treatment for cerebral folate deficiency linked to autism, bypassing its usual rigorous approval process, which has raised concerns among experts about the premature endorsement and lack of dosage guidelines, emphasizing the need for further research.
Leucovorin, a drug approved for chemotherapy side effects, is being explored as a potential treatment for autism related to cerebral folate deficiency. While some small studies and anecdotal reports suggest improvements in communication and behavior, there is not enough rigorous scientific evidence to confirm its safety and efficacy for autism, raising concerns about premature approval and unregulated use. The FDA plans to update its labeling to reflect potential benefits, but experts warn against overestimating the current evidence.
The Trump administration approved the use of leucovorin, a vitamin B derivative, as a treatment for autism based on limited and weak evidence, sparking criticism from experts who emphasize the need for more rigorous studies before such treatments are widely adopted. Despite some promising small studies, the scientific community remains cautious, highlighting the importance of controlled clinical trials and the risks of premature approval.